tracking
Gila Therapeutics Completes Phase I Clinical Trial

Gila Therapeutics Completes Phase I Clinical Trial

Obesity drug developer, Gila Therapeutics, recently took a big step toward FDA approval for its new weight control treatment, completing its Phase I clinical trial in August. Gila is developing a novel intra-oral delivery of PYY, a well-known satiety hormone, to help... Read more
Gila Therapeutics: New Solutions for the Obesity Crisis

Gila Therapeutics: New Solutions for the Obesity Crisis

Obesity is the single largest health crisis facing the world today. More than one billion people worldwide are overweight or obese, accounting for 38% of the population. In the U.S., a full 68% of adults, or some 200 million people, are overweight. On average, obese... Read more